EU harms research

On April 26th, 2023, the EU Commission released the Pharmaceutical Package (General Pharmaceutical Legislative Revision), a long-awaited regulatory project aimed at implementing the EU pharmaceutical strategy. The package includes two legislative proposals: a new directive and a new regulation. These proposals seek to establish a comprehensive legal framework for all medicinal products in the EU, simplifying and replacing the existing pharmaceutical legislation.

Eine junge Pharmazeutin blickt rätselnd auf ein Klemmbrett.

Implementing the Commission's draft in its current form will not accomplish its actual goal of improving the availability of innovative medicines for patients throughout Europe. On the contrary, creating a complex system with lowered standards of intellectual property protection in Europe will hinder rather than enhance investment in research, development, and production of medicines. This holds especially true for member states, such as Germany that are facing pressures from inflation, cost-cutting policies under the Financial Stabilization Act, and subsidy policies implemented by other industrialized nations.

This trend becomes apparent when looking at the following figures: In 2002, pharmaceutical companies in the USA invested a mere two billion U.S. Dollars more in research and development compared to their European counterparts. However, today, this gap has significantly widened to 25 billion U.S. Dollars. If this trend persists and is further intensified by new regulations, it is estimated that by 2040, the difference will surpass 200 billion Euros (1) .